Cyxone AB (publ) Share Price Nasdaq Stockholm
Equities
SE0007815428
Pharmaceuticals
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 20.34M 1.86M 148M |
---|---|---|---|---|---|
Net income 2024 * | -28M -2.56M -204M | Net income 2025 * | -38M -3.48M -277M | EV / Sales 2024 * | - |
Net cash position 2024 * | 1M 91.56K 7.29M | Net cash position 2025 * | 41M 3.75M 299M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.72
x | P/E ratio 2025 * |
-0.52
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.97% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 19/05/21 | |
Founder | 58 | 31/12/14 | |
Malin Lindskog
DFI | Director of Finance/CFO | 63 | 14/06/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 58 | 31/12/14 | |
Director/Board Member | 58 | 31/12/14 | |
Michael Oredsson
CHM | Chairman | 64 | 31/12/22 |
1st Jan change | Capi. | |
---|---|---|
+4.06% | 70.44B | |
+10.97% | 8.94B | |
-14.44% | 4.75B | |
+41.60% | 4.5B | |
+5.96% | 3.85B | |
+23.46% | 2.38B | |
-19.32% | 2.34B | |
-27.04% | 2.2B | |
+7.97% | 1.96B |